Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study
(Q45204128)
scientific article published in December 2004
scientific article published in December 2004
Language:
other details
| description | scientific article published in December 2004 |
External Links
| (P356) |
10.1080/10428190400004521
|
| (P698) |
15621757
|